Mirabegron And Ureteral Stent-related Pain (MAP) Trial
Status:
Recruiting
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
Ureteric stents are used often following ureteroscopy for prevention of obstruction from
edema and/or stone fragments.
Up to 75% of patients experience pain following stenting, as well as lower urinary tract
symptoms (LUTS) such as finding blood in the urine, voiding often, the need to urinate
quickly resulting in a significant source of morbidity. The negative impact of stents results
in a significant impact on health related quality of life.
There is no standard of care for managing ureteric stent pain and lower urinary tract
symptoms following surgery. A combination of α-blockers, antimuscarinics, acetaminophen,
nonsteroidal anti-inflammatory drugs and opioids are currently the mainstay for treatment of
post-operative pain and LUTS following stenting.
Mirabegron is a beta-agonist that mediate relaxation of the detrusor muscle and has been
useful in treating overactive bladder (OAB) which has similar symptoms to patients with an
ureteric stent in place. Our goal is to assess if mirabegron can improve symptoms and
decrease the need for additional pain medications.
The investigators hypothesize that Mirabegron is effective in decreasing ureteral stent
related LUTS and pain.
Phase:
Phase 3
Details
Lead Sponsor:
St. Michael's Hospital, Toronto Unity Health Toronto